69.34 +0.01 (0.01%)
After hours: 6:01PM EDT
|Bid||69.34 x 1000|
|Ask||69.65 x 1100|
|Day's range||68.78 - 70.18|
|52-week range||33.44 - 71.60|
|PE ratio (TTM)||N/A|
|Earnings date||23 Jul 2018 - 27 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||65.10|
J. P. Morgan analysts recommended investors continue to overweight small-cap stocks, seeing them as shielded from the escalating risk of a trade war and U.S. dollar volatility
Exact Sciences broke out to a record high Wednesday after the biotech showed its newest blood test could detect curable liver cancer in 91% of patients studied.
Shares jump after the American Cancer Society tweaks its recommended guidelines for cancer screening. Here's what investors need to know.
Exact Sciences Corp. , maker of a colon cancer test, had shares surge 11% in extremely heavy Wednesday trade after the American Cancer Society recommended screening for colon cancers starting five years earlier, at age 45.
After reading Exact Sciences Corporation’s (NASDAQ:EXAS) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...
Exact Sciences CEO Kevin Conroy continues to see big growth from the company’s colon-cancer test. Conroy says Exact’s screen, Cologuard, could ultimately deliver revenue of $5 to $6 billion annually, more than 10 times projected 2018 sales, as physicians and U.S. consumers embrace it. “We have an attractive long-term opportunity given the size of the market and our position in it,” Conroy told Barron’s today.
On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 33 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Exact Sciences' campaign featuring the entertainer and his wife isn't what the market expected.
Exact Sciences plunged to a six-month low Friday after first-quarter guidance was dinged by the severe flu season.
The Madison, Wisconsin-based company said it had a loss of 18 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
Exact Sciences (EXAS) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.